Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 4,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Terminated Phase 2 Interventional Results available

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

NCT04926181
View directory record Official record
Conditions
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
Interventions
Apalutamide, Cetrelimab
Drug · Biological
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

NCT02144051
View directory record Official record
Conditions
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Interventions
AZD5312
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Sarasota, Florida • Nashville, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 23, 2026, 8:14 PM EDT
Active, not recruiting Phase 1 Interventional

Long Acting Neuraxial Peri-prostatic Block in Cancer

NCT06703437
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dehydrated alcohol, Lidocaine IV
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Results available

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

NCT04148937
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY3475070, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 23, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

NCT06549465
View directory record Official record
Conditions
PSMA PET-Positive Castration-Resistant Prostate Cancer
Interventions
In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg Ac-225 rosopatamab tetraxetan, Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, Single dose 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 55 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan
Biological
Lead sponsor
Convergent Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
9
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer

NCT06178354
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions
Cryosurgery, High-Intensity Focused Ultrasound Ablation, Survey Administration
Procedure · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

NCT00087139
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ixabepilone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
162
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 114 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

NCT03821792
View directory record Official record
Conditions
Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

NCT02381236
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer

NCT04600336
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Oxybutynin Chloride, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
103
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 8:14 PM EDT
Terminated Not applicable Interventional

Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical Prostatectomy

NCT00824902
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tissue Elastography Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

NCT00006101
View directory record Official record
Conditions
Prostate Cancer
Interventions
eflornithine, Placebo
Drug
Lead sponsor
Thomas E. Ahlering
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT05730712
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Enzalutamide, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 23, 2026, 8:14 PM EDT
Recruiting No phase listed Observational

Active Surveillance for Cancer of the Prostate (ASCaP)

NCT00949819
View directory record Official record
Conditions
Prostate Cancer
Interventions
Active surveillance
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 4 Interventional

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

NCT00220194
View directory record Official record
Conditions
Cancer of Prostate
Interventions
leuprolide acetate
Drug
Lead sponsor
San Bernardino Urological Associates Medical Group Inc
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Oct 23, 2026, 8:14 PM EDT
Terminated Phase 1Phase 2 Interventional

Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

NCT00005072
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuvectin
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 23, 2026, 8:14 PM EDT
Not listed Phase 2 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

NCT02266745
View directory record Official record
Conditions
Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer, PT-112, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site
Interventions
PT-112 Injection
Drug
Lead sponsor
Promontory Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2024 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT01107392
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin Type A, Normal saline
Drug
Lead sponsor
Allergan
Industry
Eligibility
45 Years and older · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 23, 2026, 8:14 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

NCT05268666
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JBI-802
Drug
Lead sponsor
Jubilant Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Study of Irofulven in Patients With Hormone-refractory Prostate Cancer

NCT00124566
View directory record Official record
Conditions
Prostate Cancer
Interventions
Irofulven, Prednisone, Mitoxantrone, Capecitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
29
States / cities
Hot Springs, Arkansas • Jonesboro, Arkansas • Greenbrae, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of TAK-700 in Subjects With Prostate Cancer.

NCT00569153
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
TAK-700
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
19
States / cities
Beverly Hills, California • Los Angeles, California • Aventura, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

NCT00002881
View directory record Official record
Conditions
Prostate Cancer
Interventions
flutamide, goserelin acetate, leuprolide acetate, suramin, therapeutic hydrocortisone, orchiectomy
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

NCT00038194
View directory record Official record
Conditions
Prostate Cancer
Interventions
imatinib mesylate, docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 23, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Diffusion Basis Spectrum Imaging of the Prostate

NCT04420702
View directory record Official record
Conditions
Prostate Cancer
Interventions
MRI with DBSI analysis
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 8:14 PM EDT